A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

Artigo Acesso aberto Revisado por pares

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

2014; Elsevier BV; Volume: 25; Issue: 4 Linguagem: Inglês

10.1093/annonc/mdu025

ISSN

1569-8041

Autores

Ahmad Awada, Igor Bondarenko, J. Bonneterre, Elżbieta Nowara, Jean-Marc Ferrero, Ashish Bakshi, C. Wilke, Martine Piccart,

Tópico(s)

Cancer Genomics and Diagnostics

Resumo

EndoTAG-1, composed of paclitaxel embedded in liposomal membranes targeting tumor endothelial cells, was evaluated for safety and efficacy in advanced triple-negative breast cancer (TNBC).

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)